The relationship between drug concentration, mixing time, blending order and ternary dry powder inhalation performance

International Journal of Pharmaceutics

Volumn 391, Issue 1-2, 2010, Pages 137-147

  Jones, Matthew D ^a   Santo, João G F ^a   Yakub, Bilal ^a   Dennison, Mansa ^a   Master, Husein ^a   Buckton, Graham ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Blending order; Drug concentration; Fines; Mixing time; Ternary dry powder inhaler formulations; Ternary interactive mixtures

Indexed keywords

ALPHA LACTOSE; DRUG CARRIER; LACTOHALE; SALBUTAMOL SULFATE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; DRUG MIXTURE; DRUG SYNTHESIS; DRY POWDER; MOLECULAR WEIGHT; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPECTROFLUOROMETRY;

ADMINISTRATION, INHALATION; ALBUTEROL; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; LACTOSE; PARTICLE SIZE; POWDERS; RHEOLOGY; SURFACE PROPERTIES; TIME FACTORS;

EID: 77952888215     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.02.031     Document Type: Article

References (27)

1. Adi H., Larson I., Chiou H., Young P., Traini D., Stewart P. Role of agglomeration in the dispersion of salmeterol xinafoate from mixtures for inhalation with differing drug to fine lactose ratios. J. Pharm. Sci. 2008, 97:3140-3152.
2. Adi H., Larson I., Chiou H., Young P.M., Traini D., Stewart P. Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation. Pharm. Res. 2006, 23:2556-2565.
3. Adi H., Larson I., Stewart P.J. Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation. Int. J. Pharm. 2007, 337:229-238.
4. British Pharmacopoeia Commission British Pharmacopoeia 2008, The Stationary Office, London.
5. deVilliers M.M. Description of the kinetics of the deagglomeration of drug particle agglomerates during powder mixing. Int. J. Pharm. 1997, 151:1-6.
6. Frijlink H.W., de Boer A.H. Dry powder inhalers for pulmonary drug delivery. Expert Opin. Drug Del. 2004, 1:67-86.
7. Hartmann T., Steckel H. Proceedings of Drug Delivery To The Lungs 15 2004, 178-181. Bristol: The Aerosol Society, London, UK.
8. Islam N., Stewart P., Larson I., Hartley P. Lactose surface modification by decantation: are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures?. Pharm. Res. 2004, 21:492-499.
9. Jones, M.D., 2006. An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces. PhD Thesis, University of Bath, UK.
10. Jones M.D., Harris H., Hooton J.C., Shur J., King G.S., Mathoulin C.A., Nichol K., Smith T.L., Dawson M.L., Ferrie A.R., Price R. An investigation into the relationship between carrier-based dry powder inhalation performance and formulation cohesive-adhesive force balances. Eur. J. Pharm. Biopharm. 2008, 69:496-507.
11. Jones M.D., Hooton J.C., Dawson M.L., Ferrie A.R., Price R. An investigation into the dispersion mechanisms of ternary dry powder inhaler formulations by the quantification of interparticulate forces. Pharm. Res. 2008, 25:337-348.
12. Jones M.D., Price R. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm. Res. 2006, 23:1665-1674.
13. Louey M.D., Stewart P.J. Particle interactions involved in aerosol dispersion of ternary interactive mixtures. Pharm. Res. 2002, 19:1524-1531.
14. Lucas P., Anderson K., Staniforth J.N. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharm. Res. 1998, 15:562-569.
15. Lucas P., Clarke M.J., Anderson K., Tobyn M.J., Staniforth J.N. Proceedings of Respiratory Drug Delivery VI, vol. 1 1998, 243-250. Interpharm Press, South Carolina, Buffalo Grove, IL. R.N. Dalby, P.R. Byron, S.J. Farr (Eds.).
16. O'Brien F.E.M. The control of humidity by saturated salt solutions. J. Sci. Instrum. 1948, 25:73-76.
17. Shur J., Harris H., Jones M.D., Kaerger J.S., Price R. The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations. Pharm. Res. 2008, 25:1931-1940.
18. Srichana T., Martin G.P., Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur. J. Pharm. Sci. 1998, 7:73-80.
19. Thompson M., Ellison S.L.R., Wood R. Harmonized guidelines for single-laboratory validation of methods of analysis (IUPAC technical report). Pure Appl. Chem. 2002, 74:835-855.
20. Tuley R., Shrimpton J., Jones M.D., Price R., Palmer M., Prime D. Experimental observations of dry powder inhaler dose fluidisation. Int. J. Pharm. 2008, 358:238-247.
21. Venables H.J., Wells J.I. Powder mixing. Drug Dev. Ind. Pharm. 2001, 27:599-612.
22. Young P.M., Edge S., Traini D., Jones M.D., Price R., El-Sabawi D., Urry C., Smith C. The influence of dose on the performance of dry powder inhalation systems. Int. J. Pharm. 2005, 296:26-33.
23. Zeng X.M., Martin G.P., Marriott C., Pritchard J. Lactose as a carrier in dry powder formulations: the influence of surface characteristics on drug delivery. J. Pharm. Sci. 2001, 90:1424-1434.
24. Zeng X.M., Martin G.P., Tee S.K., Abu Ghoush A., Marriott C. Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation. Int. J. Pharm. 1999, 182:133-144.
25. Zeng X.M., Pandhal K.H., Martin G.P. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. Int. J. Pharm. 2000, 197:41-52.
26. Zeng X.M., Tee S.K., Martin G.P., Marriott C. Proceedings of Drug Delivery to the Lungs VII 1996, 40-43. Bristol: The Aerosol Society, London.
27. Zeng X.M., Tee S.K., Martin G.P., Marriott C. P195: Improving the delivery efficiency of dry powder inhalers by adding fine carrier particles to powder formulations. Thorax 1996, 51:A74.